Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Reuters NewMedia - November 30, 2005
Health officials, speaking on the eve of World AIDS Day, said an estimated 21,000 people were on ARVs in the country while latest figures showed that 1.61 million are living with
HIV/AIDS.
A majority of the patients are being treated in government hospitals where prices are cheaper, the officials said.
"We hope that we will get more people, the donors especially, to assist in putting more people on ARVs," Parirenyatwa said at the launch of the national HIV/AIDS estimates for 2005.
"I am hoping that come next year, with the global fund money coming through, we should have more people on treatment," he said but offered no further details.
The Geneva-based Global Fund to Fight AIDS, Tuberculosis and Malaria attracts, manages and disburses cash to fight the diseases - top killers in Africa.
The health officials said some 289,000 people were in need of ARVs in the southern African country and although a local company had started manufacturing generic ARVs, this was not enough to meet demand by HIV/AIDS patients.
Zimbabwe's HIV infection rate has fallen to around 20 percent of the population from 25 percent five years ago, apparently due to more condom use and fewer sex partners, a rare piece of encouraging news for a country battling its worst economic and political crisis since independence in 1980.
But Zimbabwe, with a population of some 12.5 million, still has among the world's highest HIV prevalence rates.
Zimbabwe is expected to record 134,993 new HIV infections and 142,330 AIDS cases by the end of this year while another 139,950 people are expected to die from the disease. Some 57 percent of infections and deaths are women.
051130
RE051142
Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .